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SHORT REPORT
Resistance to scrapie in PrP ARR/ARQ heterozygous sheep
is not caused by preferential allelic use
P A Caplazi, K I O’Rourke, T V Baszler
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Background: In sheep, susceptibility to scrapie, which is
similar to human prion diseases such as Kuru and variant
Creutzfeldt-Jakob disease (vCJD), is determined by prion
protein (PrP) gene (Prnp) polymorphisms. Sheep with
genotype ARQ/ARQ, denoting polymorphisms at codons
136, 154, and 171, are susceptible, whereas those with
genotypes ARR/ARQ and ARR/ARR are resistant, indicating
dominance of ARR over the ARQ allele.
Aims: Based on familial CJD E200K, 129V, where prefer-
ential use of the 200E allele in EK heterozygous individuals
confers resistance, heterozygous ARR/ARQ sheep were used
to test the hypothesis that resistance is caused by preferential
use of the ARR allele.
Methods: After assessment of equivalent PrP expression
across genotypes, allele use was analysed by sequencing
reverse transcription polymerase chain reaction derived
DNA clones containing the Prnp gene coding sequence.
Results: The ARR to ARQ ratio was 1.1 in 133 clones,
representing Prnp mRNA from three ARR/ARQ sheep,
indicating equal use of both alleles.
Conclusions: Dominance of the resistant associated allele in
sheep scrapie involves mechanisms other than the absence of
PrP derived from the disease associated ARQ allele.
S
crapie is a prion disease in sheep that, similar to Kuru
or variant Creutzfeldt-Jakob disease (vCJD), requires
both prion exposure and a genetic susceptibility.
Susceptibility is defined by amino acid polymorphisms in
the single copy prion protein (PrP) gene, Prnp.1 Specifically,
in sheep homozygous for A at position 136 and R at position
154, susceptibility is defined by R or Q at position 171.2 The
genotype ARQ/ARQ confers susceptibility, whereas (apart
from a few reported exceptions) genotypes ARR/ARQ and
ARR/ARR confer resistance. Similarly, a M/V polymorphism
at Prnp codon 129 determines susceptibility to vCJD3 and
Kuru,4 with partial resistance conferred by the V allele.
Assuming that overall PrP expression is not affected by
genotype, two main alternatives for the resistance of
heterozygous individuals exist: PrP ARR is preferentially
expressed or PrP ARR interferes with the conversion of PrP
ARQ to PrPsc.
There is a precedence for both protein–protein interference
and preferential allelic expression in genetic resistance to
acquired and hereditary transmissible spongiform encephalo-
pathies (TSEs), respectively. In the case of protein–protein
interference, dominant negative inhibition can be defined as
the ability of PrP expressed from a resistance associated allele
to render conversion of PrP to PrPsc inefficient. It has been
shown that C-terminal residues in PrP determine the ability
of PrPc to convert to PrPsc on interaction with exogenous
PrPsc,5 and it has been hypothesised that the affinity of PrPc
to an endogenous cofactor (‘‘protein X’’) required for
conversion accounts for this phenomenon.5 6 A putative
binding region for protein X has been identified.7
‘‘In the case of protein–protein interference, dominant
negative inhibition can be defined as the ability of prion
protein (PrP) expressed from a resistance associated allele
to render conversion of PrP to PrPsc inefficient’’
Supporting this concept, similar observations have been
made in vivo using a transgenic mouse model.8 Notably, with
regard to sheep scrapie, this last study used Prnp2/2 and
Prnp+/+ mice transgenic for mouse PrP with a Q167R
mutation (corresponding to the Q/R polymorphism at
position 171 of sheep PrP). Because the 167R allele rendered
Prnp+/+ mice partially resistant to intracerebral inoculation
with Rocky Mountain Laboratory prions, it was concluded
that the resistance associated 167R allele is dominant over
the wild-type allele.
From that study, it follows that overexpression of a
resistance associated allele, such as the ARR allele in sheep,
could render heterozygous carriers resistant. Indeed, incom-
plete penetrance and delayed onset of disease in hereditary
CJD E200K, 129V have been associated with preferential use
of the wild-type 200E allele over the mutant 200K allele for
PrP expression in 200EK heterozygous carriers. In five of
seven heterozygous individuals with preferential transcrip-
tion, the E to K ratio was . 50, indicating a near monoallelic
origin of PrP in these individuals.9
METHODS
Because resistance mechanisms might be shared between
hereditary and acquired prion diseases, we tested the
hypothesis that the ARR allele is transcribed to the exclusion
of ARQ in scrapie resistant ARR/ARQ heterozygous sheep.
Sites of preclinical, rather than terminal, PrPsc accumulation
were chosen for analysis because (a) primary lymphoid PrPsc
accumulation is a feature of Kuru-type prion diseases and is
essential for natural sheep scrapie3 10; (b) follicular dendritic
reticulum cells (FDCs) at peripheral accumulation sites are
early targets of accumulation in sheep scrapie10; and (c) B
cells, rather than brain, were used to demonstrate allelic
preference in familial CJD E200K.9 Before assessment of PrP
mRNA, sites of preclinical PrPsc accumulation were analysed
for PrP expression by the indirect immunofluorescence assay
(IFA) and western blotting (WB) in the ARR/ARQ (resistant)
and ARQ/ARQ (susceptible) genotypes to ensure overall
equivalent PrP expression within and between genotypes.
Abbreviations: CJD, Creutzfeldt-Jakob disease; Fab, antibody Fab
fragment(s); FDC, follicular dendritic reticulum cell; IFA, indirect
immunofluorescence assay; PCR, polymerase chain reaction; PrP, prion
protein; Prnp, prion protein gene; RT, reverse transcription; TSE,
transmissible spongiform encephalopathy; vCJD, Creutzfeldt-Jakob
disease, new variant; WB, western blotting
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Figure 1 The detection limit of PrPc by
western blotting is identical in three
resistant ARR/ARQ sheep (61, 66, 76)
and one susceptible ARQ/ARQ control
(7828). Twofold dilution series of
retropharyngeal lymph node lysates
(lane 2, 5000 mg; lane 3, 2500 mg;
lane 4, 1250 mg; lane 5, 625 mg; lane
6, 313 mg) were probed with the PrP
specific monoclonal antibody F99/
97.6.1.11 Recombinant ovine PrP served
as a positive control (lane 1). Molecular
masses in kDa are indicated on the left.
PrP, prion protein.
Figure 2 Equivalent prion protein (PrP) expression in gut associated lymphoid tissue from scrapie resistant and susceptible sheep by indirect
immunofluorescence assay. (A) Ileal Peyer’s patch from sheep 61 with the resistant PrP genotype ARR/ARQ. PrP is ubiquitously expressed in round cells
and stroma of a lymphoid follicle, and staining is particularly strong within the germinal centre. PrP (monoclonal antibody 7A12) is green (Alexa
green); nuclei are blue (DAPI); bar, 20 mm. (B) Ileal Peyer’s patch from sheep 61 with resistant PrP genotype ARR/ARQ. No fluorescent signal with
irrelevant isotype matched control antibody (anti-Neospora caninum monoclonal antibody 5B6–25); bar, 20 mm. (C) Ileal Peyer’s patch from sheep
7828 with susceptible PrP genotype ARQ/ARQ. Expression of PrP is similar to the heterozygous ARR/ARQ sheep shown in (A). PrP (monoclonal
antibody 7A12) is green (Alexa green); nuclei are blue (DAPI); bar, 20 mm. (D) Ileal Peyer’s patch from sheep 66 (ARR/ARQ). Abundant PrP (green) is
expressed in follicular dendtritic reticulin cells (FDCs) (red). Dual label immunofluorescence assay (IFA): PrP (7A12), Alexa green; FDC (CNA.42),
Texas red; nuclei are blue (DAPI); bar, 20 mm. (E) Detail of panel (D), granular, mostly membrane associated PrP expression (arrows) in an FDC. (F)
Ileal Peyer’s patch from sheep 7828 (ARQ/ARQ). Abundant PrP (green) is expressed by FDCs (red) in a pattern indistinguishable from ARR/ARQ
sheep. Dual label IFA: PrP (7A12), Alexa green; FDC (CNA.42), Texas red; nuclei are blue (DAPI); bar, 20 mm.
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Three juvenile, healthy, not scrapie exposed ARR/ARQ
Suffolk lambs (61, 66, and 76) and one matched healthy
ARQ/ARQ control lamb (7828) were used. For WB, 100 mg
samples of retropharyngeal lymph node were lysed in 900 ml
lysis buffer (10mM Tris/HCl (pH 7.5) containing 0.5% NP-40
and 0.5% deoxycholate), incubated with 200 mg/ml DNase,
and centrifuged to remove cell debris. The PrP fraction was
concentrated by centrifugation of lysate supernatants in a
filter device with a 10 kDa cut off. Serial twofold dilutions of
concentrated lysate supernatants (20 ml/lane; wet tissue
equivalents: 5000, 2500, 1250, 625, and 313 mg) were used
in sodium dodecyl sulfate polyacrylamide gel electrophoresis
on 14% gels. The positive control comprised 25 ng/lane of
ovine recombinant PrP. The anti-PrP monoclonal antibody
F99/97.6.1,11 followed by enhanced chemoluminescence
(ECL; Amersham Biosciences, Piscataway, New Jersey,
USA), were used for the detection of bands. For IFA,
cryostatic sections were obtained from samples of ileum
and mesenteric lymph node, fixed in P-fix (methanol/
phosphate buffered saline/glacial acetic acid, 50/49/1 vol/vol),
and probed with monoclonal antibodies 7A1212 for PrP and
CNA.4213 for FDCs. PrP immunoreactivity was visualised
using isotype specific biotinylated Fabs with subsequent
tyramide amplification of an Alexa green signal (Molecular
Probes, Eugene, Oregon, USA). FDCs were visualised using
antibody Fab fragments (Fabs) conjugated with Texas red
(Jackson ImmunoResearch Laboratories, West Grove,
Pennsylvania, USA).
RESULTS
PrP expression was seen in the germinal centre of lymphoid
follicles by single label IFA. Genotype specific differences in
PrP expression were not evident by the detection limit in WB
using serially diluted lymph node lysates (fig 1). The PrPc
detection limit in two separate experiments was 625 mg wet
tissue equivalents for all sheep tested, indicating relative
equivalence of PrP expression. Furthermore, PrP signal
intensity and distribution detected by IFA were similar for
the ARR/ARQ (resistant) and ARQ/ARQ (susceptible) geno-
types (fig 2A–C). Similarly, differences in the cellular
specificity of PrP expression by dual IFA (fig 2D–F) were
not found, indicating that genotype specific variations in PrP
expression did not confound the interpretation of the allelic
ratio of the PrP transcripts. In both genotypes, double label
IFA confirmed the expression of PrP in FDCs, cells that are
crucial in the pathogenesis of scrapie.
The allelic ratio of PrP transcripts was determined in three
ARR/ARQ sheep by sequence analysis of reverse transcription
polymerase chain reaction (RT-PCR) derived DNA clones.
Cloning and sequencing were chosen over probe based
approaches to detect the single base polymorphism at
position 171 because the procedures used (RNA isolation,
reverse transcription, PCR, and cloning) are random with
respect to the single base polymorphism. PrP transcripts
isolated from mesenteric (first experiment) or retropharyn-
geal lymph nodes (second experiment) were analysed in two
independent experiments. Total RNA was isolated from
lymph nodes and reverse transcribed using oligo-dT primers
after DNase digestion. cDNA was amplified by PCR (anneal-
ing at 60 C˚) using the primers PrP148F 59-AACCGCTATC
CACCTCAG and PrP637R 59-CCACTCGCTCCATTATCT, which
span a 491 bp fragment within the PrP coding region
containing codons 136, 154, and 171. Absence of genomic
DNA in PCR was controlled for by mock RT reactions. PCR
products were A–U cloned into pDrive (Qiagen, Valencia,
California, USA) and sequenced through a commercial
service (Amplicon Express, Pullman, Washington, USA). A
single G/A polymorphism at base 365 of the insert corre-
sponding to the second base in codon 171 was detected, as
reported previously.1 The first experiment yielded 60 clones
with an R to Q ratio of 37 : 23. The second experiment
resulted in 73 clones with a ratio of 33 : 40. Overall, a slight
predominance of ARR over ARQ was seen with a ratio of 1.1
(fig 3A), which was not significantly different from the
expected ratio of 1.0 (sign test, p = 0.63). Furthermore, the
combined mean number of ARR and ARQ clones of all three
sheep did not differ significantly (fig 3B), and there were no
differences between the ARR and ARQ transcripts in the
individual sheep (fig 3C). Accordingly, the hypothesis of
differential allelic use, particularly preferential use of 171R,
was rejected.
Figure 3 Use of the ARR and ARQ alleles in cDNA clones of the prion protein gene (Prnp) obtained from the lymph nodes of three ARR/ARQ
heterozygous sheep (two experiments). (A) No significant difference in the use of the ARR and ARQ alleles in the total number of Prnp clones examined
in all three sheep (sign test, p = 0.63). (B) No significant difference in the use of the ARR and ARQ alleles in the mean of the Prnp clones examined in
all three sheep. Error bars are one standard deviation of the mean. (C) No significant difference in the use of the ARR and ARQ alleles in the Prnp
clones examined from the individual sheep. Error bars are one standard deviation of two experiments.
Take home messages
N Unlike resistance in hereditary familial Creutzfeldt-
Jakob disease E200K, dominance of the resistant
associated allele in sheep scrapie involves mechanisms
other than the absence of prion protein derived from
the disease associated ARQ allele
N Mechanisms of genetic resistance vary among trans-
missible spongiform encephalopathies and may not be
shared between hereditary familial and Kuru-type
acquired prion diseases
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DISCUSSION
Therefore, unlike resistance in hereditary familial CJD
E200K,9 resistance to scrapie in ARR/ARQ heterozygous
sheep cannot be attributed to monoallelic mRNA transcrip-
tion. Rather, our data show that both alleles are used with
approximately equal frequency for Prnp transcription. We
conclude that mechanisms of genetic resistance vary among
TSEs and may not be shared between hereditary familial and
Kuru-type acquired prion diseases. The relative genetic
resistance of ARR/ARQ sheep must involve mechanisms
other than simple absence of PrP ARQ. Such mechanisms
may include interference of PrP ARR with PrPsc formation,
directly by reducing the likelihood of productive initial
interaction with the infectious prion, or indirectly by
inhibiting interaction of nascent PrPsc with accessory
molecules (protein X hypothesis).7 Finally, the relative lack
of easily convertible substrate PrP ARQ may prolong the
incubation period beyond the lifespan of the animal.
‘‘The relative genetic resistance of ARR/ARQ sheep must
involve mechanisms other than simple absence of prion
protein ARQ’’
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